Connor, Clark & Lunn Investment Management Ltd. Protagonist Therapeutics, Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$24.66 - $34.8 $256,340 - $361,745	-10,395 Reduced 11.16%	82,791 $2.87 Million
Q1 2024 May 09, 2024	SELL	$21.79 - $32.15 $312,817 - $461,545	-14,356 Reduced 13.35%	93,186 $2.7 Million
Q4 2023 Feb 09, 2024	SELL	$14.05 - $23.44 $448,925 - $748,954	-31,952 Reduced 22.91%	107,542 $2.47 Million
Q3 2023 Nov 13, 2023	SELL	$16.68 - $23.66 $399,169 - $566,207	-23,931 Reduced 14.64%	139,494 $2.33 Million
Q2 2023 Aug 10, 2023	BUY	$18.02 - $29.36 $746,046 - $1.22 Million	41,401 Added 33.93%	163,425 $4.51 Million
Q1 2023 May 09, 2023	SELL	$10.78 - $25.38 $783,490 - $1.84 Million	-72,680 Reduced 37.33%	122,024 $2.81 Million
Q4 2022 Feb 10, 2023	BUY	$7.36 - $11.17 $25,840 - $39,217	3,511 Added 1.84%	194,704 $2.12 Million
Q3 2022 Nov 10, 2022	BUY	$7.86 - $11.71 $1.5 Million - $2.24 Million	191,193 New	191,193 $1.61 Million
Q3 2020 Nov 12, 2020	SELL	$15.19 - $22.4 $434,403 - $640,595	-28,598 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$6.19 - $18.84 $177,021 - $538,786	28,598 New	28,598 $505,000

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

Farallon Capital Management LLC San Francisco, CA

5.86M
Shares

$238 Million
1.32% of portfolio
Black Rock Inc. New York, NY

5.76M
Shares

$234 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.43M
Shares

$221 Million
3.89% of portfolio
Vanguard Group Inc Valley Forge, PA

4.22M
Shares

$172 Million
0.0% of portfolio
State Street Corp Boston, MA

3.18M
Shares

$130 Million
0.01% of portfolio

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account